Table 2 Clinical characteristics of the patient groups according to hs-CRP level (cardiovascular risk)
Compared groups and clinical data | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
low CVR | medium CVR | high CVR | |
n = 11 | n = 30 | n = 24 | |
Males | 7 (63.6%) | 14 (46.7%) | 4 (16.7%) |
Females | 4 (36.4%) | 16 (53.3%) | 20 (83.3%)*^ |
Ages (years) | 56.6 ± 12.7 | 55.4 ± 9.9 | 57.2 ± 13.0 |
Hypertension | 8 (72.7%) | 26 (86.7%) | 20 (83.3%) |
Ischemic heart disease | 3 (27.3%) | 11 (36.7%) | 6 (25.0%) |
Myocardial infarct | 1 (9.1%) | 6 (20.0%) | 1 (4.2%) |
Cardiac failure | 3 (27.3%) | 11 (36.7%) | 11 (45.8%) |
IFG/IGT | 5 (45.5%) | 21 (70.0%) | 12 (50.0%) |
CKD | 1 (9.1%) | 7 (23.3%) | 7 (29.2%) |
Stroke | 0 | 1 (3.3%) | 2 (8.3%) |
Cerebral arteries failure | 1 (9.1%) | 2 (6.7%) | 0 |
Hyperuricemia | 3 (27.3%) | 11 (36.7%) | 12 (50.0%) |
Dyslipidemia | 11 (100.0%) | 29 (96.7%) | 21 (87.5%) |
Tobacco smoking | 0 | 3 (10.0%) | 2 (8.3%) |
ACEI | 9 (81.8%) | 27 (90.0%) | 11 (45.8%)^^ |
ARB | 1 (9.1%) | 6 (20.0%) | 10 (41.7%) |
Diuretics | 6 (54.5%) | 16 (53.3%) | 16 (66.7%) |
CCA | 4 (36.4%) | 10 (33.3%) | 6 (25.0%) |
BB | 3 (27.3%) | 10 (33.3%) | 12 (50.0%) |
Spironolactone | 2 (18.2%) | 5 (16.7%) | 11 (45.8%)^ |
ARA | 2 (18.2%) | 4 (13.3%) | 1 (4.2%) |
ASA | 1 (9.1%) | 11 (36.7%) | 5 (20.8%) |
Hypolipemic treatment a | 10 (90.9%) | *15 (50.0%) | **10 (41.7%) |